Arcturus’ unlocked nucleomonomer agents (UNAs) can improve the in vivo efficiency of small interfering RNA (siRNA)-mediated gene silencing and potentially improve the efficiency of messenger RNA (mRNA)-mediated protein replacement. UNAs are RNA analogues in which the C2′-C3′ bond of the ribose ring is absent (see figure below).
One or more UNAs can be positioned strategically along a nucleic acid strand to manipulate the chemical properties of the molecule. Addition of a single UNA in siRNA therapeutics can enable more efficient suppression of target protein production.
March 27, 2020
Arcturus COVID-19 Vaccine to Benefit from Duke-NUS Genetic Correlation System
March 11, 2020
Arcturus Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results
March 4, 2020
Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR™ Technology